Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

Exclusion Criteria

• •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
• •Administration of chronic immunosuppressants or other immune-modifying drugs since birth or planned administration during the study.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after.
• •Previous vaccination against diphtheria, tetanus, pertussis, polio or Haemophilus influenzae type b.
• •History of, or intercurrent, diphtheria, tetanus, pertussis, hepatitis B, polio and/or Haemophilus influenzae type b.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.
• •Major congenital defects
• •Serious chronic illness
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
• •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
• •Acute disease at the time of enrollment.